Pharmaceutical Industry in Mexico
Over the past decade, pharmaceutical companies have pushed the scientific envelope, working at the cellular and molecular levels to dramatically advance the treatment of disease.
Mexico’s pharmaceutical policy environment is in a period of rapid evolution, with simultaneous policy development, refinement and ongoing implementation. This handicaps Mexico’s efforts to achieve policy goals efficiently at the present time, and also makes policy assessment and even accurate description difficult.
Mexico, along with almost all OECD countries, has witnessed growth rates in health expenditures that have surpassed general rates of inflation and, as in many cases, a main driver has been spending on pharmaceuticals. Between 1999 and 2004, the real annual growth rate in pharmaceutical spending in Mexico was 8%, the fifth highest among the 24 OECD countries for which data were available for this period. Like most OECD countries, annual growth in pharmaceutical expenditures in Mexico was greater than that for total health spending (net of pharmaceutical spending), which was only 4.9% for this period.
Aruvian's R'search brings you a complete analysis of the Pharmaceutical Industry in Mexico. The report covers a brief profile of the global pharmaceutical industry, the trends in the industry, competition in the industry, and key trends in the pharmaceutical supply chain in Mexico. The report also looks at strategies for market entry, the role of R&D in the Mexican Pharmaceutical Industry, and the role of the government in the industry.
Complete with a comprehensive section on the clinical trials, market investment opportunities going on in the Mexican pharmaceutical industry, Aruvian’s latest research is a collection of all you need to know about Mexico’s Pharmaceutical Industry.
Mexico’s pharmaceutical policy environment is in a period of rapid evolution, with simultaneous policy development, refinement and ongoing implementation. This handicaps Mexico’s efforts to achieve policy goals efficiently at the present time, and also makes policy assessment and even accurate description difficult.
Mexico, along with almost all OECD countries, has witnessed growth rates in health expenditures that have surpassed general rates of inflation and, as in many cases, a main driver has been spending on pharmaceuticals. Between 1999 and 2004, the real annual growth rate in pharmaceutical spending in Mexico was 8%, the fifth highest among the 24 OECD countries for which data were available for this period. Like most OECD countries, annual growth in pharmaceutical expenditures in Mexico was greater than that for total health spending (net of pharmaceutical spending), which was only 4.9% for this period.
Aruvian's R'search brings you a complete analysis of the Pharmaceutical Industry in Mexico. The report covers a brief profile of the global pharmaceutical industry, the trends in the industry, competition in the industry, and key trends in the pharmaceutical supply chain in Mexico. The report also looks at strategies for market entry, the role of R&D in the Mexican Pharmaceutical Industry, and the role of the government in the industry.
Complete with a comprehensive section on the clinical trials, market investment opportunities going on in the Mexican pharmaceutical industry, Aruvian’s latest research is a collection of all you need to know about Mexico’s Pharmaceutical Industry.
A. EXECUTIVE SUMMARY
B. THE GLOBAL PHARMACEUTICAL INDUSTRY – A BRIEF PROFILE
B.1 Industry Definition
B.2 Product Characterization
B.2 Industry Overview
B.3 Industry Forecast
C. MEXICO’S PHARMACEUTICAL INDUSTRY
C.1 Industry Overview
C.2 Market Segments
C.3 Competition in the Industry
C.4 Pharmaceutical Expenditure
C.5 Industry Activity
C.6 Distribution Channels
C.7 R&D in the Industry
C.8 Clinical Trials
C.9 Emergence of Pharmacogenomics
C.10 Pharmaceutical Supply Chain
C.11 Demand Scenario for Pharmaceuticals
C.12 Import/Export Scenario
D. MEXICO’S OTC PHARMACEUTICAL SECTOR
D.1 Sector Definition
D.2 Industry Overview
D.3 Market Segments
D.4 Market Share
D.5 Competition in the Industry
D.6 Distribution Channels
D.7 Sector Forecast
E. PHARMACEUTICAL PRICING AND REIMBURSEMENT IN MEXICO
E.1 Mexico’s Regulatory Environment
E.2 Intellectual Property Rights
E.3 Product Approval Process
E.4 Pricing Policies
E.5 Coverage Scheme for Pharmaceuticals
E.6 Purchasing of Pharmaceuticals
E.7 Initiatives Influencing Pharmaceutical Consumption
F. INDUSTRY FORECAST
G. MAJOR INDUSTRY PLAYERS
G.1 Abbott Laboratories
G.2 Boehringer Ingelheim GmbH
G.3 GlaxoSmithKline Plc
G.4 Novartis AG
G.5 Pfizer Inc
G.6 Roche Holding AG
G.7 Sanofi-Aventis Group
G.8 Wyeth
H. APPENDIX
I. GLOSSARY OF TERMS
B. THE GLOBAL PHARMACEUTICAL INDUSTRY – A BRIEF PROFILE
B.1 Industry Definition
B.2 Product Characterization
B.2 Industry Overview
B.3 Industry Forecast
C. MEXICO’S PHARMACEUTICAL INDUSTRY
C.1 Industry Overview
C.2 Market Segments
C.3 Competition in the Industry
C.4 Pharmaceutical Expenditure
C.5 Industry Activity
C.6 Distribution Channels
C.7 R&D in the Industry
C.8 Clinical Trials
C.9 Emergence of Pharmacogenomics
C.10 Pharmaceutical Supply Chain
C.11 Demand Scenario for Pharmaceuticals
C.12 Import/Export Scenario
D. MEXICO’S OTC PHARMACEUTICAL SECTOR
D.1 Sector Definition
D.2 Industry Overview
D.3 Market Segments
D.4 Market Share
D.5 Competition in the Industry
D.6 Distribution Channels
D.7 Sector Forecast
E. PHARMACEUTICAL PRICING AND REIMBURSEMENT IN MEXICO
E.1 Mexico’s Regulatory Environment
E.2 Intellectual Property Rights
E.3 Product Approval Process
E.4 Pricing Policies
E.5 Coverage Scheme for Pharmaceuticals
E.6 Purchasing of Pharmaceuticals
E.7 Initiatives Influencing Pharmaceutical Consumption
F. INDUSTRY FORECAST
G. MAJOR INDUSTRY PLAYERS
G.1 Abbott Laboratories
G.2 Boehringer Ingelheim GmbH
G.3 GlaxoSmithKline Plc
G.4 Novartis AG
G.5 Pfizer Inc
G.6 Roche Holding AG
G.7 Sanofi-Aventis Group
G.8 Wyeth
H. APPENDIX
I. GLOSSARY OF TERMS
